Regaining compliance with Nasdaq's listing requirements is a significant positive development for Altamira Therapeutics. It removes the immediate risk of delisting, which can be a major concern for investors and can negatively impact stock price. With this risk mitigated, investor confidence may improve, potentially leading to a short-term positive impact on the stock price. However, the long-term impact will depend on the company's ongoing performance and market conditions.